Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-A02171-38 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood.
The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation.
The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients undergoing atrial fibrillation catheter ablation | Patients undergoing scheduled atrial fibrillation catheter ablation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| atrial fibrillation catheter ablation | Procedure | The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of atrial fibrillation recurrence. | At 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of major adverse cardiovascular events (MACE) including hospitalization for acute heart failure, cardiovascular death, stroke, myocardial infarction | At 3 years | |
| Incidence of major bleeding (defined by BARC≥3 bleeding) | At 3 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients referred to the Lille University Hospital for schedulled Atrial fibrillation catheter ablation
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sandro Ninni, MD | Contact | 0320445962 | +33 | sandro.ninni@chru-lille.fr |
| Name | Affiliation | Role |
|---|---|---|
| Sandro Ninni, MD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Coeur-Poumon, CHU | Recruiting | Lille | France |
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D001145 | Arrhythmias, Cardiac |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Buffy coat, plasma, serum, PBMCs
|